Sugi Predict

Sugi Predict / Compounds / SCHEMBL14656377

SCHEMBL14656377

SCHEMBL14656377

O=Cc1ccc(Oc2cccc(Cl)c2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ TTR P02766 2/20 0.46
▸ LMNA P02545 2/20 0.43
▸ IGFBP3 P17936 1/20 0.43
▸ FFAR1 O14842 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ PPARD Q03181 1/20 0.42
▸ EPAS1 Q99814 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RHEB Q15382 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8549646 0.89 TTR (0.51) MAPTKMT2AMEN1TTRLMNA
SCHEMBL14656395 0.85 MAOA (0.48) MAPTKMT2AMEN1TTRLMNA
SCHEMBL14656430 0.84 HTR2A (0.46) TTREPAS1ALDH1A1GAASLC6A4
SCHEMBL23120903 0.83 HSD17B10 (0.47) MAPTKMT2AMEN1TTRIGFBP3
SCHEMBL13218233 0.83 TTR (0.64) MAPTKMT2AMEN1TTRLMNA
SCHEMBL14667749 0.82 TTR (0.49) MAPTKMT2AMEN1TTRLMNA
SCHEMBL4016806 0.82 TTR (0.56) MAPTKMT2AMEN1TTRLMNA
SCHEMBL14656113 0.82 CYP1A2 (0.43) MAPTKMT2AMEN1LMNAFFAR1
SCHEMBL9904833 0.81 TTR (0.43) MAPTKMT2AMEN1TTRLMNA
SCHEMBL3993806 0.81 TTR (0.62) MAPTKMT2AMEN1TTRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103827116-B As LP-PLA2the 2,3-glyoxalidine of inhibitor also [1,2-c] pyrimidine-5 (1H)-one compound 葛兰素集团有限公司 2016-08-31 — — CN disclosed
CN-103827118-B Bicyclic pyrimidin ketone compound GLAXO GROUP LTD. (GB) 2016-03-09 — — CN disclosed
US-9273054-B2 Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2016-03-01 — — US disclosed
US-9273054-B2 Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2016-03-01 — — US disclosed
US-9273054-B2 Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2016-03-01 — — US disclosed
US-8975400-B2 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2015-03-10 — — US disclosed
US-8975400-B2 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2015-03-10 — — US disclosed
US-8975400-B2 2,3-dihydroimidazo[1, 2-c] pyrimidin-5(1 H)-one compounds use as LP-PLA2 inhibitors GLAXO GROUP LIMITED (GB) 2015-03-10 — — US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
US-20140179715-A1 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
US-20140179715-A1 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
CN-103827118-A Bicyclic pyrimidone compounds GLAXO GROUP LTD 2014-05-28 — — CN disclosed
CN-103827116-A 2, 3-dihydroimidazolo [1,2-c] pyrimidin-5 (1H)-one compound useful as LP-PLA2inhibitor GLAXO GROUP LTD 2014-05-28 — — CN disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — US disclosed
WO-2013013503-A1 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-31 — — WO disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179715-A1 2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS PLA2G4A, PLA2G4C, PLA2G4B MAPT 2285/4885KMT2A 2580/4885MEN1 2860/4885
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS PLA2G7, PLA2G4A, PLA2G1B MAPT 2037/4885KMT2A 3447/4885MEN1 3960/4885
US-20130030012-A1 COMPOUNDS LPCAT1, PLA2G7, PLAAT2 MAPT 1291/4885KMT2A 3366/4885MEN1 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.